PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Hypertension (Quinapril hydrochloride - Hypertension)

Records returned : 48 (on 21 Nov 2024 at 17:00:15). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
02.05.05
Quinapril hydrochloride
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.06.02
Nifedipine
Hypertension
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
02.04.00
Atenolol
Hypertension
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.04.00
Bisoprolol fumarate
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.06.02
Amlodipine
Hypertension
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Preferred
01.07.04
02.06.02
Diltiazem hydrochloride
Hypertension
Green
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Tildiem Retard (TWICE daily) are the lowest cost brand in Primary Care for patients requiring a tablet formulation.
01.07.04
02.06.02
Hypertension
Green
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Angitil SR capsules (TWICE daily) or Zemtard XL or Slozem (ONCE daily) are the lowest cost brands for Primary Care.
02.06.02
Lercanidipine hydrochloride
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.06.02
Nifedipine
Hypertension
Green
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Tensipine MR (Twice daily) and Adipine XL (once daily) are the preferred tablet brands.
02.06.02
Hypertension
Green
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Coracten SR (Twice daily) and Coracten XL (once daily) are the preferred capsule brands.
02.02.01
Indapamide
Hypertension
Green
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Preferred thiazide diuretic
02.04.00
Co-tenidone (Atenolol/chlortalidone)
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.05.04
Doxazosin mesilate
Hypertension
Green
Formulations :
  • Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway.
02.05.05
04.07.04
Candesartan cilexetil
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Preferred angiotensin II receptor blocker
02.05.05
Losartan potassium
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Preferred angiotensin II receptor blocker
02.05.05
Irbesartan
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.05.05
Olmesartan medoxomil
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.05.05
Telmisartan
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.05.05
Valsartan
Hypertension
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.05.05
Ramipril
Hypertension
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
02.05.05
Lisinopril
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
02.05.02
Moxonidine
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
ASPH restrict use to cardiology only.
02.05.05
Enalapril maleate
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred ACE inhibitor during breastfeeding (where an ACE inhibitor is appropriate)
Lisinopril / Hydrochlorothiazide
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
MHRA alert: Hydrochlorothiazide risk of non-melanoma skin cancer
02.05.05
Perindopril erbumine
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
2mg, 4mg and 8mg tablets
Irbesartan / Hydrochlorothiazide
Hypertension
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
MHRA alert: Hydrochlorothiazide risk of non-melanoma skin cancer
Valsartan with hydrochlorothiazide
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
MHRA alert: Hydrochlorothiazide risk of non-melanoma skin cancer
02.05.04
07.04.01
Prazosin hydrochloride
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
Only the 500mcg tablets are licensed in the UK. 2mg and 5mg tablets as special order or import only (much more expensive)
02.04.00
Metoprolol tartrate
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.04.00
Nebivolol
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.04.00
04.07.04
Propranolol hydrochloride
Hypertension
Green (see narrative)
Formulations :
  • Modified release capsules
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Not a preferred beta blocker for hypertension. The cardio-selective betablockers, bisoprolol or atenolol are the preferred options
02.02.01
Bendroflumethiazide
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Indapamide is the preferred diuretic treatment option. No requirement to switch from bendroflumethiazide in stable patients.
02.04.00
Carvedilol
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.05.05
Captopril
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Not 1st line
02.02.03
Spironolactone
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Adjunct in resistant hypertension
02.05.05
Lisinopril
Hypertension
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
Liquid is very expensive (>£200 for 150ml - Drug Tariff Sep 2024).
02.05.02
04.07.04
Clonidine hydrochloride
Hypertension
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserved for severe / resistant hypertension.
Initiation and stabilisation by the specialist before transfer of prescribing to GP.
02.05.01
Hydralazine hydrochloride
Hypertension
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribing in primary care on specialist recommendation only. Reserved for severe / resistant hypertension.
02.05.01
Hypertension
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Hypertensive emergency (including pregnancy) or hypertension with renal complications
02.06.02
Nicardipine hydrochloride
Hypertension
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Specialist only
02.02.01
Chlortalidone
Hypertension
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Not for initiation in new patients.
02.02.01
Metolazone
Hypertension
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
02.05.05
Aliskiren
Hypertension
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
NHS England guidance DO NOT ROUTINELY PRESCRIBE
02.04.00
Celiprolol hydrochloride
Hypertension
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not for initiation in new patients. Existing patients may remain on therapy.
02.05.04
Doxazosin mesilate
Hypertension
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Step 4 of the hypertension pathway.
Use immediate release tablets
02.05.05
Azilsartan medoxomil
Hypertension
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
02.05.05
Eprosartan
Hypertension
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
02.05.05
Perindopril arginine
Hypertension
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
NHS England guidance DO NOT ROUTINELY PRESCRIBE
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More